Anixa Biosciences (NASDAQ:ANIX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Anixa Biosciences (NASDAQ:ANIX) from a sell rating to a hold rating in a research report sent to investors on Monday morning.

Several other equities analysts have also recently issued reports on the company. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, February 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.50.

Anixa Biosciences Trading Up 4.2%

NASDAQ ANIX opened at $2.70 on Monday. The company’s fifty day simple moving average is $2.94 and its 200-day simple moving average is $3.53. Anixa Biosciences has a 52 week low of $2.33 and a 52 week high of $5.46. The stock has a market cap of $90.53 million, a P/E ratio of -8.18 and a beta of 0.48.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. On average, research analysts expect that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Activity

In related news, Director Arnold M. Baskies acquired 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Wednesday, January 28th. The stock was acquired at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the transaction, the director directly owned 135,000 shares of the company’s stock, valued at $410,400. This trade represents a 8.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds have recently added to or reduced their stakes in ANIX. NewEdge Advisors LLC acquired a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $33,000. Cetera Investment Advisers bought a new position in Anixa Biosciences in the 4th quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. grew its holdings in Anixa Biosciences by 2,000.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after buying an additional 10,000 shares in the last quarter. Benjamin Edwards Inc. acquired a new stake in Anixa Biosciences in the 2nd quarter valued at approximately $37,000. Finally, Millennium Management LLC acquired a new stake in Anixa Biosciences in the 4th quarter valued at approximately $38,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.